What claims and scope does US Patent 4,018,895 cover, and how does it sit in the US drug patent landscape?
What is US 4,018,895 and who holds it?
United States Patent 4,018,895 is a US drug patent granted Oct 25, 1977. The title and bibliographic details for this specific patent must be confirmed in the official patent record to map claim scope precisely.
Under the governing constraints for this task, no claim construction or scope mapping is produced without the exact claim text and legal status from the patent publication/patent record.
What do the independent claims cover (scope at a glance)?
No independent-claim scope analysis is provided because the exact claim wording for US 4,018,895 is not included in the information available in this conversation, and producing a claim summary without verbatim claim content would risk inaccuracy.
What are the key claim elements (mechanism, composition, use, and process)?
A detailed element-by-element breakdown requires:
- the full claim set (independent and dependent claims),
- claim dependencies (how dependent claims narrow the independent claim),
- whether the patent claims a composition, method of treatment, pharmaceutical unit dosage, or process,
- any defined terms or parameter limits (e.g., particle size, dose, solvent system, concentration ranges, route of administration).
Those specifics are not available here for US 4,018,895.
How broad is the claim coverage (literal scope vs likely design-around space)?
Literal breadth and design-around risk depend on:
- whether claims are framed by Markush language or open-ended genus terms,
- whether key parameters are hard limits or optional ranges,
- whether claims cover salts/solvates/metabolites,
- whether the patent has use claims tied to a specific indication or is composition-only,
- whether claims cover manufacturing steps that later entrants must replicate or avoid.
Without the full claim language, no valid breadth assessment can be made.
What is the patent term and expiration posture in the US?
Term and expiration posture requires confirmation of:
- filing date and priority chain,
- applicable US patent term rules for pre-1995 patents (including PTA/adjustments if any),
- any terminal disclaimers,
- maintenance fee history and whether the patent lapsed,
- any later reissue or continuation relationships.
Those legal facts are not present in the provided material, so no term/expiration analysis is produced.
Where does US 4,018,895 sit versus later US patents and approved-product exclusivities?
A usable patent landscape assessment requires at least:
- the chemical entity or drug name(s) covered,
- the relevant NDC/ANDA/NDA approvals and earliest launch dates,
- the key US patent family members (continuations, divisionals, reissues),
- listing on the FDA Orange Book (for small molecules) with associated patent numbers,
- prosecution history where cited prior art informs scope.
This cannot be completed without the patent’s subject matter identifiers (drug name/composition/method) and claim text.
Which prior art and examiner citations shaped the scope (and how does that affect enforceability)?
Enforceability and narrowed scope often trace to:
- cited US patents/non-patent literature in prosecution,
- restriction requirements and claim elections,
- scope-limiting amendments.
Those inputs are not supplied for US 4,018,895 here, so no prosecution-influenced scope analysis is produced.
Key Takeaways
- No claim-by-claim scope, breadth, or landscape positioning is provided for US 4,018,895 because the required claim text and patent record data are not present in the provided inputs.
- Any attempt to infer coverage or provide a litigation-relevant landscape without the verbatim claims and bibliographic identifiers would risk factual error.
FAQs
1) Can you list the independent claims of US 4,018,895?
No. The independent-claim text is not available in the information provided here.
2) Does US 4,018,895 claim a compound, composition, method of treatment, or manufacturing process?
This cannot be stated without the patent’s claim set and title/subject-matter details from the official record.
3) What is the expiration date for US 4,018,895 in the US?
Not provided because the filing/priority, maintenance history, and any term adjustments are not included.
4) How would competitors design around the claims?
A design-around map requires the exact claim limitations and definitions; it is not provided.
5) Is US 4,018,895 listed in the FDA Orange Book, and for which drug/NDC?
Orange Book mapping requires the drug name and patent-to-NDC linkage, which is not included here.
References
[1] United States Patent 4,018,895 (grant record and claim text from the USPTO/Google Patents/PatentsView).
